Matthew Roden (MPM Capital)
After leading Celgene buyout, Matthew Roden leaves Bristol Myers Squibb for venture capital firm
The past four years at Bristol Myers Squibb have been busy for Matthew Roden. The senior VP and head of enterprise strategy was behind the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
